MX2010011012A - Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen. - Google Patents

Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen.

Info

Publication number
MX2010011012A
MX2010011012A MX2010011012A MX2010011012A MX2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A MX 2010011012 A MX2010011012 A MX 2010011012A
Authority
MX
Mexico
Prior art keywords
allergen
administration
seasonal
dosage form
dose
Prior art date
Application number
MX2010011012A
Other languages
English (en)
Spanish (es)
Inventor
Eike Gunther Wuestenberg
Eckhard-Carl Albrecht Puchert
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010011012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of MX2010011012A publication Critical patent/MX2010011012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010011012A 2008-04-11 2009-04-08 Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen. MX2010011012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
MX2010011012A true MX2010011012A (es) 2010-11-12

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011012A MX2010011012A (es) 2008-04-11 2009-04-08 Inmunoterapia en mucosas, especifica de alergeno, con dosificacion inicial despues de inicio de estacion de polen.

Country Status (12)

Country Link
US (2) US9248097B2 (https=)
EP (1) EP2265285B1 (https=)
JP (2) JP5618981B2 (https=)
CN (1) CN102014954A (https=)
AU (1) AU2009235490B2 (https=)
BR (1) BRPI0911433A2 (https=)
CA (1) CA2720455A1 (https=)
DE (1) DE202008006598U1 (https=)
EA (1) EA019202B1 (https=)
ES (1) ES2406391T3 (https=)
MX (1) MX2010011012A (https=)
WO (1) WO2009124954A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20120100163A1 (en) * 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US20120100164A1 (en) 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
EP2681555B1 (en) 2011-02-25 2020-04-08 Benaroya Research Institute Detection of an allergic disorder
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
CA3208225A1 (en) 2012-01-16 2013-07-25 Elizabeth Mckenna Compositions and methods for the treatment of hepatitic diseases and disorders
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
PL194804B1 (pl) 1998-03-16 2007-07-31 Alk Abello As Zrekombinowany alergen, sposób przygotowywania zrekombinowanego alergenu, kompozycja farmaceutyczna oraz zastosowanie zrekombinowanego alergenu do przygotowywania leku do wywoływania odpowiedzi immunologicznej u osobnika i do przygotowywania leku do leczenia, zapobiegania lub osłabiania reakcji alergicznych
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
ATE414773T1 (de) 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
CN1668737A (zh) 2002-05-16 2005-09-14 阿尔克-阿贝洛有限公司 重组Bet.V.1过敏原突变体及其方法和制备
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2554337A1 (en) 2004-02-06 2005-08-25 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
CA2556557A1 (en) * 2004-02-26 2005-09-09 Alk Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
CN101065146B (zh) * 2004-11-10 2012-11-14 爱尔开-阿贝优公司 通过过敏反应疫苗的粘膜给药预防性治疗过敏反应的方法
WO2006050729A2 (en) 2004-11-10 2006-05-18 Alk-Abellò A/S Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
CA2682054A1 (en) * 2007-03-28 2008-10-02 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Also Published As

Publication number Publication date
BRPI0911433A2 (pt) 2016-07-26
EP2265285A1 (en) 2010-12-29
ES2406391T3 (es) 2013-06-06
EP2265285B1 (en) 2013-03-20
JP5618981B2 (ja) 2014-11-05
HK1147946A1 (en) 2011-08-26
EA019202B1 (ru) 2014-01-30
DE202008006598U1 (de) 2008-10-02
US9248097B2 (en) 2016-02-02
AU2009235490A1 (en) 2009-10-15
US20110142934A1 (en) 2011-06-16
AU2009235490B2 (en) 2013-10-24
EA201071182A1 (ru) 2011-06-30
WO2009124954A1 (en) 2009-10-15
US20140127298A1 (en) 2014-05-08
JP2011516521A (ja) 2011-05-26
CA2720455A1 (en) 2009-10-15
CN102014954A (zh) 2011-04-13
JP2015013891A (ja) 2015-01-22

Similar Documents

Publication Publication Date Title
AU2009235490B2 (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
EP2436395B1 (en) An allergen dosage form
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
MXPA05009079A (es) Forma de dosificacion que tiene una matriz de sacarido.
AU2008231722B2 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
EP1974745B1 (en) Use of an adjuvanted allergy vaccine formulation for subcutaneous administration
CN101340892A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration
HK1087008B (en) An allergen dosage form
HK1147215A (en) An allergen dosage form
CN103933562A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途

Legal Events

Date Code Title Description
FG Grant or registration